The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.

Malkin SJP, Russel-Szymczyk M, Psota M, Hlavinkova L, Hunt B

Advances in therapy5 Jun 2019Cited by 11 (Europe PMC)

PMID31168765PMCIDPMC6822857DOI10.1007/s12325-019-00965-yPepBankPUB-31168765

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Semaglutide aloneIn silicoOther
In a lifetime model of adults with type 2 diabetes and BMI above 35, once-weekly semaglutide 0.5 mg gave 0.04 more QALYs than dulaglutide 1.5 mg.
In plain wordsA computer model projected that semaglutide 0.5 mg would add 0.04 quality-adjusted life years compared with dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life expectancy, semaglutide 0.5 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Metabolic and weight
Measurements
QALY gain
0.04 QALYs
semaglutide 0.5 mg vs dulaglutide 1.5 mg
Source sentences
Summary
Once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in quality-adjusted life expectancy of 0.04 and 0.07 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3116876501
02Computer modelNot a test of Semaglutide aloneIn silicoOther
In a lifetime model of adults with type 2 diabetes and BMI above 35, once-weekly semaglutide 1 mg gave 0.07 more QALYs than dulaglutide 1.5 mg.
In plain wordsA computer model projected that semaglutide 1 mg would add 0.07 quality-adjusted life years compared with dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
IncreaseQuality-adjusted life expectancy, semaglutide 1 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Metabolic and weight
Measurements
QALY gain
0.07 QALYs
semaglutide 1 mg vs dulaglutide 1.5 mg
Source sentences
Summary
Once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in quality-adjusted life expectancy of 0.04 and 0.07 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3116876502
03Computer modelNot a test of Semaglutide aloneIn silicoOther
In a lifetime model, once-weekly semaglutide 0.5 mg saved EUR 20 per patient against dulaglutide 1.5 mg.
In plain wordsA computer model projected a saving of EUR 20 for each patient treated with semaglutide 0.5 mg compared with dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
DecreaseLifetime medical cost, semaglutide 0.5 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Metabolic and weight
Measurements
Cost saving per patient
20 EUR
semaglutide 0.5 mg vs dulaglutide 1.5 mg
Source sentences
Summary
Lifetime medical costs were similar, with cost savings of EUR 20 and EUR 140 per patient with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3116876503
04Computer modelNot a test of Semaglutide aloneIn silicoOther
In a lifetime model, once-weekly semaglutide 1 mg saved EUR 140 per patient against dulaglutide 1.5 mg.
In plain wordsA computer model projected a saving of EUR 140 for each patient treated with semaglutide 1 mg compared with dulaglutide 1.5 mg.
Peptide
Semaglutide
Outcome
DecreaseLifetime medical cost, semaglutide 1 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Metabolic and weight
Measurements
Cost saving per patient
140 EUR
semaglutide 1 mg vs dulaglutide 1.5 mg
Source sentences
Summary
Lifetime medical costs were similar, with cost savings of EUR 20 and EUR 140 per patient with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3116876504
05Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Slovak diabetes model, dulaglutide yielded lower quality-adjusted life expectancy than semaglutide 0.5 mg.
In plain wordsIn a computer model of diabetes, dulaglutide yielded lower quality-adjusted life expectancy than semaglutide 0.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseQuality-adjusted life expectancy versus semaglutide 0.5 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 0.5 mg
Outcome group
Quality of life · Whole body
Measurements
Semaglutide QALY advantage
0.04 QALYs
semaglutide 0.5 mg versus dulaglutide
Source sentences
Summary
Once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in quality-adjusted life expectancy of 0.04 and 0.07 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
Summary · context
Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3116876505
06Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Slovak diabetes model, dulaglutide yielded lower quality-adjusted life expectancy than semaglutide 1 mg.
In plain wordsIn a computer model of diabetes, dulaglutide yielded lower quality-adjusted life expectancy than semaglutide 1 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseQuality-adjusted life expectancy versus semaglutide 1 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 1 mg
Outcome group
Quality of life · Whole body
Measurements
Semaglutide QALY advantage
0.07 QALYs
semaglutide 1 mg versus dulaglutide
Source sentences
Summary
Once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in quality-adjusted life expectancy of 0.04 and 0.07 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
Summary · context
Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3116876506
07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Slovak diabetes model, dulaglutide had similar lifetime costs, with a small cost advantage for semaglutide 0.5 mg.
In plain wordsIn a computer model, lifetime costs were similar, with a small cost advantage for semaglutide 0.5 mg over dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLifetime medical costs versus semaglutide 0.5 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 0.5 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Semaglutide cost savings
20 EUR per patient
semaglutide 0.5 mg versus dulaglutide
Source sentences
Summary
Lifetime medical costs were similar, with cost savings of EUR 20 and EUR 140 per patient with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
Summary · context
Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3116876507
08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Slovak diabetes model, dulaglutide had similar lifetime costs, with a small cost advantage for semaglutide 1 mg.
In plain wordsIn a computer model, lifetime costs were similar, with a small cost advantage for semaglutide 1 mg over dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseLifetime medical costs versus semaglutide 1 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 1 mg
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Semaglutide cost savings
140 EUR per patient
semaglutide 1 mg versus dulaglutide
Source sentences
Summary
Lifetime medical costs were similar, with cost savings of EUR 20 and EUR 140 per patient with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
Summary · context
Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3116876508
09Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Slovak diabetes model, semaglutide 0.5 mg economically dominated dulaglutide.
In plain wordsIn a computer model, semaglutide 0.5 mg offered better modeled health outcomes at lower costs than dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableEconomic dominance versus semaglutide 0.5 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Both doses of once-weekly semaglutide were therefore considered dominant versus dulaglutide 1.5 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus dulaglutide 1.5 mg in Slovakia.
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
Summary · context
Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3116876509
10Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Slovak diabetes model, semaglutide 1 mg economically dominated dulaglutide.
In plain wordsIn a computer model, semaglutide 1 mg offered better modeled health outcomes at lower costs than dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableEconomic dominance versus semaglutide 1 mg
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Both doses of once-weekly semaglutide were therefore considered dominant versus dulaglutide 1.5 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
The aim of the present study was to evaluate the long-term cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus dulaglutide 1.5 mg in Slovakia.
Summary · context
Clinical and cost outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects were based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7.
Summary · context
Patients were modeled to receive once-weekly semaglutide or dulaglutide for 3 years, after which treatment was intensified to basal insulin.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3116876510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02648204

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Novo Nordisk A/Sn = 1,2016 Jan 2016 to 19 May 2017

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 15 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.